PMOS和MASLD之间的相互作用：病理生理学和循证营养干预
The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.
摘要(中文译文)
多内分泌代谢性卵巢综合征（PMOS）被认为是育龄女性中最常见的内分泌疾病，根据现行鹿特丹诊断标准，其估计患病率约为18%。在确诊PMOS的女性中，常可观察到血脂异常、胰岛素抵抗、高雄激素血症、中心性肥胖和慢性炎症等情况。这些情况使此类个体发生代谢功能障碍相关脂肪性肝病（MASLD）的风险增加，而MASLD是全球最常见的慢性肝病，影响约25%的全球人口。PMOS与MASLD是两种相互关联的代谢性疾病，具有重叠的危险因素。本叙述性综述旨在探讨PMOS与MASLD之间潜在病理生理联系，并评估针对性营养干预的疗效。本文对近30篇关于PMOS和MASLD营养策略的文章进行了分析，包括饮食模式、以宏量营养素为重点的饮食策略以及膳食补充剂干预的研究。本综述得出结论：一种联合方案——包括抗炎饮食模式、omega-3补充剂和肌醇——可作为临床医生和营养师管理同时患有PMOS和MASLD的女性的良好循证初始策略。值得注意的是，这些建议的大多数证据来自仅关注PMOS或MASLD人群的研究。目前缺乏涉及同时患有两种疾病个体的研究。未来研究应优先开展长期随机对照试验，纳入来自不同背景、确诊同时患有PMOS和MASLD的女性。这些疾病无论单独还是同时存在，都在给全球育龄女性带来越来越沉重的负担。随着进一步研究的开展，营养干预可能成为管理PMOS和MASLD的主要治疗策略，而非辅助治疗策略。
Abstract
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is recognized as the most prevalent endocrine disorder among women of reproductive age, with an estimated prevalence of approximately 18% according to current Rotterdam diagnostic criteria. Conditions such as dyslipidemia, insulin resistance, hyperandrogenism, central adiposity, and chronic inflammation are frequently observed in women diagnosed with PMOS. These conditions predispose such individuals to an increased risk of developing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which is the most prevalent chronic liver disease worldwide, affecting approximately 25% of the global population. PMOS and MASLD represent two interconnected metabolic disorders that share overlapping risk factors. The purpose of this narrative review is to investigate the underlying pathophysiological connections between PMOS and MASLD and to assess the efficacy of targeted nutritional interventions. An analysis of nearly 30 articles concerning nutritional strategies for PMOS and MASLD was conducted, including studies on dietary patterns, macronutrient-focused dietary strategies, and dietary supplement interventions. The review concludes that a combined approach-comprising an anti-inflammatory dietary pattern, omega-3 supplementation, and myo-inositol-serves as a good evidence-based initial strategy for clinicians and dietitians managing women with coexisting PMOS and MASLD. It is noteworthy that most of the evidence for these recommendations comes from studies that focus solely on either PMOS or MASLD populations. Studies involving individuals with both conditions are currently lacking. Future research should prioritize long-term randomized controlled trials involving women from diverse backgrounds diagnosed with both PMOS and MASLD. These conditions, whether independently or concurrently, are imposing an increasing burden on women of reproductive age worldwide. As further research is conducted, nutritional interventions may serve as primary rather than supplementary therapeutic strategies for the management of PMOS and MASLD.
如何引用
AMA
Ashley Graef, Monique J LeMieux. The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.. Nutrients. 2026; doi:10.3390/nu18121948.
APA
Ashley Graef, Monique J LeMieux (2026). The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.. Nutrients. https://doi.org/10.3390/nu18121948
GB/T 7714
Ashley Graef, Monique J LeMieux. The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.[J]. Nutrients, 2026 doi:10.3390/nu18121948.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出